In vivo studies on ischemia-/reperfusion-related arrhythmias obtained with NCX blockers yielded controversial results, since the majority of experiments failed to show any antiarrhythmic effect of SEA-0400 [73,74,75]. This evidence concerns the gene TLX2 and cardiac arrhythmia.